Showing 5101-5110 of 6803 results for "".
- Nemolizumab Performs Well in AD, PNhttps://practicaldermatology.com/news/nemolizumab-performs-well-in-ad-pn/2462061/Galderma’s nemolizumab performed well in three pivotal phase III trials in atopic dermatitis (AD) and prurigo nodularis (PN), according to late-breaking data presented at the 2023 European Academy of Dermatology and Venereology (EADV) congress in Berlin. Nemolizuma
- Positive Phase 2a Data Shown for MC2-32, a Novel HSP90 Inhibitor in HShttps://practicaldermatology.com/news/positive-phase-2a-data-shown-for-mc2-32-a-novel-hsp90-inhibitor-in-hs/2462058/MC2-32 (previously RGRN-305), a first-in-class, oral therapy HSP90 inhibitor, performed well in Hidradenitis Suppurativa (HS), according to Phase 2a results presented during a late-breaking session at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Berlin.
- AbbVie’s JAK inhibitor RINVOQ "Measures Up" in ADhttps://practicaldermatology.com/news/abbvies-jak-inhibitor-rinvoq-measures-up-in-ad/2462057/New Phase 3 research supports the long-term efficacy and safety of RINVOQ (upadacitinib) in moderate to severe atopic dermatitis (AD), according to data analyses from the Measure Up 1, Measure Up 2, and AD Up studies presented at the European Academy of Dermatology and Venereology (EADV) Congress
- Protagonist Therapeutics JNJ-2113 Update: IL23-Blocker Advances Into Multiple Clinical Development Programs for PsO, UChttps://practicaldermatology.com/news/jnj-2113-update-il23-blocker-advances-into-multple-clinical-development-programs-for-pso-uc/2462054/Protagonist Therapeutics, Inc. will be eligible to receive $60 million in milestone payments in the fourth quarter for the advancement of JNJ-2113 (formerly known as PN-235) into multiple clinical development programs led by Janssen Biotech, Inc., a Johnson & Johnson company (Janssen), the Co
- NPF Update: Group Hosts 25th Dermatology Residents’ Meeting and Research Symposium: A Cure for Allhttps://practicaldermatology.com/news/npf-update-group-hosts-25th-dermatology-residents-meeting-and-research-symposium-a-cure-for-all/2462049/The National Psoriasis Foundation (NPF) celebrated the 25th anniversary of the annual Dermatology Residents’ Meeting on October 7 and 8, 2023 in Washington, D.C. Experts and co-chairs Brad P. Glick, DO, MPH, FAAD, and Samuel Hwang MD, PhD. hosted the silver anniversary event with
- FDA Approves Arcutis’ ZORYVE (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11https://practicaldermatology.com/news/fda-approves-arcutis-zoryve-roflumilast-cream-03-for-treatment-of-psoriasis-in-children-ages-6-to-11/2462045/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis, including intertriginous areas, to children ages 6 to 11 years. “T
- Dermavant Appoints John Darden as New Head of Marketinghttps://practicaldermatology.com/news/dermavant-appoints-john-darden-as-new-head-of-marketing/2462043/John Darden is the new Vice President of Marketing at Dermavant Sciences. In his most recent role as Executive Director, Marketing and U.S. Brand Lead, Mr. Darden directed the healthcare professional, consumer, and field-based marketing strategies for Otezla (apremilast) tablet.
- When Lightning Strikes: A Case Study of Staphylococcal Scalded Skin Syndrome in a 55-year-old Manhttps://practicaldermatology.com/news/when-lightning-strikes-a-case-study-of-staphylococcal-scalded-skin-syndrome-in-a-55-year-old-man/2462042/Five months after being struck by lightning, a 55-year-old male presented with a 2-day history of an erythematous rash. The patient noted his skin had been excessively dry since the lightning strike, and he recently added a new essential oil to his bath. His medical history includes liver failure
- Regenerative Medicine Breakthrough: Researchers Create BioPrinted Full Thickness Skinhttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-researchers-create-bioprinted-full-thickness-skin/2462041/New bioprinted skin may accelerate wound healing, support healthy extracellular matrix remodeling, and aid in complete wound recovery, according to research out of the Wake Forest Institute for Regenerative Medicine (WFIRM). Available grafts are often temporary, or if permanent, h
- Measuring ctDNA May Lead to Alternative Treatment Options and Better Outcomes in Advanced Melanomahttps://practicaldermatology.com/news/measuring-ctdna-may-lead-to-alternative-treatment-options-and-better-outcomes-in-advanced-melanoma/2462040/Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma. A new study found that measuring ctDNA in the blood of patients with BRAF wild-type (BRAF WT) s